Understanding and targeting this plasticity mechanism, which spans tumour initiation, progression, transformation and resistance, is crucial for developing precise combination interventions (e.g., epigenetic inhibitors combined with EGFR‐TKI, ICI, AKT/MYC or DLL3‐targeted therapies) to improve clinical efficacy and prolong patient survival. This evidence concerns the gene MYC and neoplasm.